Vertex (VRTX) Higher After Pharmasset (VRUS) Hep-C Trial Issues
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Join SI Premium – FREE
Vertex Pharmaceuticals (Nasdaq: VRTX) is moving higher following news earlier from Pharmasset, Inc. (Nasdaq: VRUS) that will amend the design of the QUANTUM Phase 2b trial after detecting laboratory abnormalities associated with liver function in subjects receiving PSI-938 300 mg once daily.
Vertex has competing Hep-C products.
Vertex is over 4 percent higher in pre-open trading.
While Vertex is higher, a number of Hep-C drug makers are lower.
Inhibitex (Nasdaq: INHX) are down 37 percent, shares of Idenix (Nasdaq: IDIX) are down 16 percent and shares of Achillion (Nasdaq: ACHN) down almost 5 percent.
Vertex has competing Hep-C products.
Vertex is over 4 percent higher in pre-open trading.
While Vertex is higher, a number of Hep-C drug makers are lower.
Inhibitex (Nasdaq: INHX) are down 37 percent, shares of Idenix (Nasdaq: IDIX) are down 16 percent and shares of Achillion (Nasdaq: ACHN) down almost 5 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Nscale targets up to $3B in US IPO as soon as September - Bloomberg
- Gossamer Bio raises up to $250M in private placement for PAH drug
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
